Facing orphan adoption challenges
This article was originally published in Scrip
No one doubts the considerable impact the introduction of orphan drug legislation has had on the development of treatments for very rare diseases. However, this progress would not have been achieved were it not for the alliances that have been created among the various stakeholders. Indeed, greater understanding of the fundamental causes of disease, highly motivated patient advocacy groups and the growing interest of big pharma in a space that was until recently the exclusive reserve of biotechs are having a big impact on the prospects for treating patients with rare diseases.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.